Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Kessler

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Oncotarget|January 7, 2016
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factorCaroline Brand, Christoph Schliemann, Janine Ring, et al.
Blood|April 19, 2012
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patientsRuediger Liersch, Joachim Gerss, Christoph Schliemann, et al.
Annals of Hematology|May 24, 2020
Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myelomaChristine Eisfeld, Eva Eßeling, Ramona Wullenkord, et al.
Plos One|May 13, 2016
Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment DecisionLars Henning Schmidt, Benedikt Vietmeier, Gerrit Kaleschke, et al.
BMJ Open|August 30, 2020
Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)Leopold Hentschel, Stephan Richter, Hans-Georg Kopp, et al.
Oncology Letters|October 8, 2014
Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosisMichael Mohr, Christoph Schliemann, Christoph Biermann, et al.
Journal of Medicinal Chemistry|March 19, 2013
Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factorChristian Schwöppe, Caroline Zerbst, Max Fröhlich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomasChristoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
Plos One|May 23, 2018
Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 casesChristoph Schliemann, Andrea Kerkhoff, Paula Hesse, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancerLars Henning Schmidt, Janine Stucke-Ring, Caroline Brand, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Oncotarget|January 7, 2016
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factorCaroline Brand, Christoph Schliemann, Janine Ring, et al.
Blood|April 19, 2012
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patientsRuediger Liersch, Joachim Gerss, Christoph Schliemann, et al.
Annals of Hematology|May 24, 2020
Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myelomaChristine Eisfeld, Eva Eßeling, Ramona Wullenkord, et al.
Plos One|May 13, 2016
Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment DecisionLars Henning Schmidt, Benedikt Vietmeier, Gerrit Kaleschke, et al.
BMJ Open|August 30, 2020
Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)Leopold Hentschel, Stephan Richter, Hans-Georg Kopp, et al.
Oncology Letters|October 8, 2014
Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosisMichael Mohr, Christoph Schliemann, Christoph Biermann, et al.
Journal of Medicinal Chemistry|March 19, 2013
Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factorChristian Schwöppe, Caroline Zerbst, Max Fröhlich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomasChristoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
Plos One|May 23, 2018
Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 casesChristoph Schliemann, Andrea Kerkhoff, Paula Hesse, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancerLars Henning Schmidt, Janine Stucke-Ring, Caroline Brand, et al.
Pageof 8